Literature DB >> 21915041

Nausea and vomiting perspectives among children receiving moderate to highly emetogenic chemotherapy treatment.

Cheryl Rodgers1, Deborah Kollar, Olga Taylor, Rosalind Bryant, Katie Crockett, Mary Ann Gregurich, Marilyn Hockenberry.   

Abstract

BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) are common adverse effects, but occurrences among pediatric oncology patients are not well documented.
OBJECTIVE: The primary aim was to describe anticipatory, acute, and delayed CINV among children with cancer from the child's, caregiver's, and nurse's perspective. A secondary aim evaluates the correlation of CINV among the child's, caregiver's, and nurse's perspectives.
METHODS: CINV perspectives were evaluated before, during, and after a single course of highly or moderately emetogenic chemotherapy. CINV were evaluated among 40 pediatric cancer patients using the Adapted Rhodes Index of Nausea and Vomiting for Pediatrics, among their caregivers using the Adapted Rhodes Index of Nausea and Vomiting for Parents, and among their nurses using the National Cancer Institute Nausea and Vomiting Grading Criteria.
RESULTS: CINV were reported by the patient, caregiver, and nurse at all times, with the most frequent reports occurring in the delayed period. Patient's mean total nausea and vomiting scores increased significantly over time. Patient reports of anticipatory, acute, and delayed CINV correlated with caregiver and nurse reports except for anticipatory nausea between the nurse and patient.
CONCLUSIONS: CINV occurred throughout the chemotherapy course, with delayed CINV occurring most frequently and with greater severity and distress. Caregiver CINV reports correlated closely with patient reports. IMPLICATIONS FOR PRACTICE: Nurses need to be aware of the frequency, severity, and distress of CINV throughout the chemotherapy regimen. CINV can occur before and after chemotherapy treatment and should be assessed so that appropriate interventions can be implemented.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21915041     DOI: 10.1097/NCC.0b013e3182281493

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  6 in total

1.  Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children's Oncology Group.

Authors:  Priya Patel; Paula D Robinson; Andrea Orsey; Jason L Freedman; Anne-Marie Langevin; Debbie Woods; Lillian Sung; L Lee Dupuis
Journal:  Pediatr Blood Cancer       Date:  2016-01-27       Impact factor: 3.167

2.  Perspectives of children, family caregivers, and health professionals about pediatric oncology symptoms: a systematic review.

Authors:  Lei Cheng; Liying Wang; Mengxue He; Sheng Feng; Yehui Zhu; Cheryl Rodgers
Journal:  Support Care Cancer       Date:  2018-05-17       Impact factor: 3.603

3.  Symptom Monitoring in Pediatric Oncology Using Patient-Reported Outcomes: Why, How, and Where Next.

Authors:  Allison Barz Leahy; Chris Feudtner; Ethan Basch
Journal:  Patient       Date:  2018-04       Impact factor: 3.883

4.  Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors.

Authors:  Kelly Duggin; Kelly Tickle; Gina Norman; Jie Yang; Chong Wang; Shane J Cross; Amar Gajjar; Belinda Mandrell
Journal:  J Pediatr Oncol Nurs       Date:  2014-06-27       Impact factor: 1.636

5.  Smartphone App to Self-Monitor Nausea During Pediatric Chemotherapy Treatment: User-Centered Design Process.

Authors:  Astrid Eliasen; Mikkel Kramme Abildtoft; Niels Steen Krogh; Catherine Rechnitzer; Jesper Sune Brok; René Mathiasen; Kjeld Schmiegelow; Kim Peder Dalhoff
Journal:  JMIR Mhealth Uhealth       Date:  2020-07-20       Impact factor: 4.773

6.  Evaluating pictorial support in person-centred care for children (PicPecc): a protocol for a crossover design study.

Authors:  Stefan Nilsson; Angelica Wiljén; Jonas Bergquist; John Chaplin; Ensa Johnson; Katarina Karlsson; Tomas Lindroth; Anneli Schwarz; Margaretha Stenmarker; Gunilla Thunberg; Linda Esplana; Eva Frid; Malin Haglind; Angelica Höök; Joakim Wille; Joakim Öhlen
Journal:  BMJ Open       Date:  2021-05-04       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.